Covance Inc.  

(Public, NYSE:CVD)   Watch this stock  
Find more results for Watson Laboratories Inc�
88.98
+1.64 (1.88%)
Jul 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 86.63 - 89.80
52 week 79.11 - 106.50
Open 87.21
Vol / Avg. 969,504.00/378,595.00
Mkt cap 5.11B
P/E 28.04
Div/yield     -
EPS 3.17
Shares 57.41M
Beta 0.91
Inst. own 96%
Jul 30, 2014
Q2 2014 Covance Inc Earnings Call - 9:30AM EDT - Add to calendar
Jul 29, 2014
Q2 2014 Covance Earnings Release
Jun 11, 2014
Covance Inc at William Blair & Company LLC Growth Stock Conference
Jun 10, 2014
Covance at Goldman Sachs Healthcare Conference - Webcast
Jun 3, 2014
Covance at Jefferies Global Healthcare Conference - Webcast
May 20, 2014
Covance at UBS Global Healthcare Conference - Webcast
May 14, 2014
Covance at Bank of America Merrill Lynch Health Care Conference - Webcast
May 7, 2014
Covance at Robert W. Baird & Co. Inc Growth Stock Conference - Webcast
May 6, 2014
Covance Annual Shareholder Meeting
May 2, 2014
Q1 2014 Covance Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 7.63% 6.91%
Operating margin 10.04% 8.37%
EBITD margin - 15.31%
Return on average assets 7.98% 7.40%
Return on average equity 12.64% 12.48%
Employees 12,501 -
CDP Score - -

Address

210 Carnegie Center
PRINCETON, NJ 08540
United States - Map
+1-609-4524440 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Covance Inc. is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The services it provides constitutes two segments: early development services, which includes discovery support services, preclinical services and clinical pharmacology services, and late-stage development services, which includes central laboratory, Phase II-IV clinical development, and market access services. In 2011, Covance acquired certain assets of TRAC Microbiology, Inc., a food microbiology and chemistry laboratory. In May 2014, the Company acquired Medaxial.

Officers and directors

Joseph L. Herring Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Alison A. Cornell Chief Financial Officer, Vice President
Age: 51
Bio & Compensation  - Reuters
Richard F. Cimino Executive Vice President, Group President - Clinical Development
Age: 54
Bio & Compensation  - Reuters
Deborah L. Keller Tanner Executive Vice President, Group President - Research and Development Laboratories
Age: 51
Bio & Compensation  - Reuters
William E. Klitgaard Corporate Senior Vice President, Chief Information Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James W. Lovett Esq. Corporate Senior Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
John E. Watson Corporate Senior Vice President, Chief Commercial Officer, President - Strategic Partnering
Age: 54
Bio & Compensation  - Reuters
Brian H. Nutt Principal Accounting Officer, Senior Director of External Reporting
Age: 44
Bio & Compensation  - Reuters
Gary E. Costley Ph.D. Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Robert L. Barchi M.D., Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters